Background: Viral infection of the bronchial epithelium disrupts the barrier proper-
| INTRODUCTION
The bronchial epithelium plays a key role in immune responses to the environment, and its integrity is paramount in defence against infection, allergens and pollution. Inherited or acquired defects in innate defences in asthma and COPD render the bronchial epithelium susceptible to environmental factors, with cycles of epithelial damage and repair playing a key role in both the initiation and progression of these chronic airways diseases. 1, 2 Respiratory viral infections, particularly with rhinovirus (RV), the most prevalent respiratory virus, cause exacerbations of asthma and COPD, which in turn are associated with increased morbidity and mortality. 3, 4 People with asthma and healthy individuals are equally at risk of upper respiratory tract infection with RV; however, those with atopic asthma have more frequent and more severe lower respiratory tract symptoms. 5 Respiratory viral infections cause epithelial barrier disruption that predisposes to antigen sensitisation in asthma 1 and bacterial infection in COPD. 3, 4 Therapeutics that improve bronchial epithelial repair increase in the resistance of the airways to these sequelae, limiting the consequences of viral infection as well as other aggravating factors that disrupt the barrier function, such as proteolytic allergens, oxidants in cigarette smoke, air pollutants and proinflammatory cytokines. disruption of the actin cytoskeleton and redistribution of tight junction (occludin and ZO-1) and adherens junction (E-cadherin and β-catenin) proteins from intercellular contacts to the cytoplasmic compartment without change in expression levels. 8, 9 It follows that repair of the epithelium is essential for recovery of barrier function. The restitution of normal airway epithelium involves the formation of a provisional fibrin matrix 10 and migration of neighbouring epithelial cells over the first 12-24 hours to cover denuded surfaces as the primary repair mechanism, followed by proliferation of progenitor cells to restore cell numbers and differentiation to restore function. 11 Within the airway, injury to the epithelium is followed by an inflammatory response involving neighbouring epithelial cells, fibroblasts, macrophages, endothelial cells and plasma exudation. 11 The released soluble factors supporting epithelial repair include growth factors, cytokines, matrikines and
MMPs. 11 MMP-1, MMP-7 and MMP-9 are proposed to facilitate epithelial repair by promoting cell migration. 11 We previously showed that bronchial epithelial repair following mechanical disruption was dependent on the local expression of coagulation factors including tissue factor (TF), fibrinogen and factor XIIIA in NHBE and 16HBE14o-cell monolayers and the formation of a provisional fibrin matrix. 10 It has been shown that MMP-13 (collagenase-3) impairs fibrin formation via degradation of fibrinogen 12 and other coagulation factors 13 as well as matrix proteins. Further, poly I:C as a model of most replicating virus 14 strongly stimulated expression of its receptor (TLR-3), release of pro-inflammatory cytokines and a large 25-fold increase in MMP-13 expression, without change in TIMP-1 or TIMP-2, in small airway epithelial cells. 15 We hypothesised a role for MMP-13 in limiting bronchial epithelial repair following virus infection, which has not previously been demonstrated.
We therefore investigated expression of MMP-13 in cultures of the 16HBE14o-bronchial epithelial cell line (16HBE) and normal pri- 
| MATERIALS AND METHODS

| Cell culture
Cells of the SV-40 virus-transformed human bronchial epithelial cell line, 16HBE14o-, were cultured in minimal essential media (MEM;
GibcoBRL, Paisley, UK) containing 10% heat inactivated-fetal calf serum (FCS; Sigma F9665), 2 mmol/L L-glutamine (GibcoBRL) and 1% antibiotic/antimycotic (GibcoBRL, 100 units penicillin G, 100 μg streptomycin, 250 ng amphotericin B/mL) in 75-cm 2 tissue culture grade flasks at 37°C in 5% CO 2 . At 80%-90% confluence, the cells were passaged using 0.05% trypsin-0.02% EDTA (Sigma 59418C).
After re-suspending in 1 mL full media, the cells were counted and seeded at 100 000 cells per well in a 24-well plate and cultured for 2 days to confluence in 250 μL full medium.
Normal human bronchial epithelial cells (NHBE) in bronchial epithelial growth medium (BEGM) were purchased from Lonza (Basel, CH) and are derived from the bifurcation of the trachea, and are therefore a mixture of bronchial and tracheal epithelial cells. 18 or 0.01-1 μmol/L bosentan (Sigma), 19 at the concentrations indicated in the legends and on the figures.
Control cells were untreated. Each condition was replicated in triplicate within each independent experiment. Damaged cultures were incubated for 24 hours for real-time video microscopy (see below).
After 24 hours, supernatants were removed, cell debris was cleared, and supernatants were stored at −80°C prior to analysis.
| Video microscopy
24-well plates were incubated for 24 hours at 37°C with 5% CO 2 on the stage of a Zeiss Axiovert 200M inverted microscope for live cell imaging. A 5× objective was used, and bright field images were acquired every 15 minutes for 24 hours. Volocity software (version 6.1; Quorum Technologies, Guelph, ON, USA) was used to obtain movies for each well and also to measure gap distances (μm) across each wound at five locations at each time-point. Time to closure and initial rate of closure over the first 2 hours as μm/h were calculated (mean ± SEM) using MS Excel.
| Measurement of total MMP-13, TF and endothelin (ET) in cell culture supernatants
Total MMP-13, TF and ET were measured by ELISA using Duo-Sets from R&D Systems according to the manufacturer's instructions.
Matrix metalloproteinase-13 standards were added to ELISA plates in the concentration range 62.5-4000 pg/mL, and NHBE samples diluted 1:2 for analysis in duplicate. We determined the lower limit of detection for the assay to be 21.91 pg/mL and the intraassay coefficient of variance to be 4.9% (n = 40).
Tissue factor standards were added to ELISA plates in the concentration range 7.8-500 pg/mL and samples diluted 1:2 for analysis in duplicate. We determined the lower limit of detection for the assay to be 4.81 pg/mL and the intra-assay coefficient of variance to be 4.8% (n = 28).
Endothelin-1 (ET-1) standards were added to ELISA plates in the concentration range 3.9-250 pg/mL and samples diluted 1:2 for analysis in duplicate. We determined the lower limit of detection for the assay to be 0.09 pg/mL and the intra-assay coefficient of variance to be 6.4% (n = 39).
| Statistical analysis
Statistical analysis was carried out using GraphPad Prism software (Version 7; La Jolla, CA, USA). Data for TF were analysed using oneway ANOVA. Data for the effect of WAY 170523, DMF and bosentan on the rate of epithelial repair were analysed by two-way ANOVA with Bonferroni's correction for multiple comparisons.
| RESULTS
Poly I:C significantly inhibited the initial rate of repair of both the bronchial epithelial cell line and the primary NHBE cells (Figure 1 ).
Poly I:C had a significantly greater effect and was at least an order of magnitude more potent at inhibiting wound repair in NHBE cultures over 2 hours ( Figure 1B ) and 24 hours (Figure 2 ) compared to 16HBE cultures ( Figure 1A ). Over 24 hours, the wounded 16HBE
cell layers had completely repaired in the absence or presence of poly I:C. However, although wounded NHBE layers cultured in media alone for 24 hours were largely restored to confluence (Figure 2D) , in the presence of 20 μg/mL poly I:C, cells were scattered and the wound failed to heal ( Figure 2E ).
We investigated the effect of a specific inhibitor of MMP-13 activity, WAY 170523, on the epithelial repair response in the presence of poly I:C. Results ( Figure 1A and B) show that in the presence of WAY 170523 (1 μmol/L), there was no effect of poly I:C on the rate of epithelial repair, and that WAY 170523 significantly inhibited the effect of poly I:C (20 and 1 μg/mL) in 16HBE and NHBE epithelial cell models, respectively.
We subsequently investigated whether the increased sensitivity of NHBE to poly I:C was due to higher levels of MMP-13 in NHBE compared with 16HBE cell cultures. Figure 3 shows that NHBE constitutively express and release MMP-13 into cell culture supernatants In the same concentration range, DMF alone had no effect on the rate of repair of 16HBE cell layers, but at 10-50 μmol/L, DMF significantly enhanced the rate of epithelial repair in the presence of 20 μg/mL poly I:C ( Figure 4A) . Further, the repair of NHBE monolayers strongly inhibited by poly I:C in the concentration range 1-20 μg/ mL was restored by DMF (50 μmol/L) at all concentrations of poly I: C ( Figure 4B ).
In view of our previous findings demonstrating an important role for coagulation in bronchial epithelial repair, initial experiments investigated the effect of poly I:C on TF protein expression over 24 hours ( Figure 5 ). Wounding alone had no significant effect on TF antigen levels in supernatants, as we had previously observed, 10 but poly I:C at 10 and 20 μg/mL stimulated a significant increase in TF in both intact and wounded 16HBE cell layers ( Figure 5A ). However, poly I:C had no effect on TF protein expression in wounded NHBE cell layers at any concentration ( Figure 5B ).
The nonspecific endothelin receptor antagonist, bosentan
(1-10 μmol/L), was previously shown to inhibit MMP-13 release from primary bronchial epithelial cells stimulated with TNFα. 19 We therefore investigated the effect of poly I:C on endothelin release from NHBE ( Figure 6A ) and the effect of bosentan of the rate of NHBE repair ( Figure 6B ).
Poly I:C stimulated a significant increase in the release of endothelin ( Figure 6A ). Bosentan in the concentration range 10-1000 nmol/L potently and effectively reversed the inhibitory effect of poly I:C (20 μg/mL) on the rate of NHBE repair ( Figure 6B ).
However, bosentan in the concentration range 10-1000 nmol/L had no effect on MMP-13 release from NHBE (n = 3, not shown) and, conversely, exogenously added endothelin-1 (1-100 nmol/L) did not stimulate MMP-13 release (not shown).
| DISCUSSION
This is the first report that epithelial-derived MMP-13 limits epithe- 16HBE cells (n = 8) and (B) NHBE (n = 3 or 4). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the no poly I:C control. P < 0.05 compared to poly I:C alone
(A) (B) (D) (E) (C)
F I G U R E 2 Confluent NHBE layers wounded mechanically with a pipette tip (A) were analysed using video microscopy over 24 hours, with recordings made every 15 minutes. Wounds starting to repair in media alone at 2 hours (B) failed to start repair in the presence of 20 μg/mL poly I:C at 2 hours (C). Cell layers cultured in media alone for 24 hours were largely restored to confluence (D) but in the presence of 20 μg/mL poly I:C, cells were scattered and the wound failed to heal (E). Image width = 1707 μm types, NHBE were significantly more sensitive to the effect of poly I:C (Figures 1 and 2 ). This may partly reflect the significantly increased expression of TF, a coagulation factor essential for epithelial repair, 10 in the 16HBE cells, but not in the NHBE cells, in response to poly I:C. The difference in the rate of repair may also reflect significant poly I:C-induced MMP-13 expression in NHBE cells (Figure 3 ), but not in 16HBE cells in which MMP-13 expression remained low. MMP-13 expression is positively regulated by BCYRN1, a c-MYC-activated long noncoding RNA, in non-small-cell lung cancer cells. 20 Expression of BCYRN1 is extremely low in the 16HBE cell line, which may account for the low levels of MMP-13
released from these cells. 20 BCYRN1 is generally not detected in normal tissue, 20 and physiological expression of MMP-13 is limited to tissues undergoing rapid extracellular matrix remodelling. 13 Overall, the data indicate that the 16HBE cell line, although widely used, may not be a suitable model to measure the rate of normal bronchial epithelial repair.
Targets for MMP-13 include type I, II, III, IV, X, XIV collagens, tenascin C, aggrecan core protein, perlecan, fibronectin, fibrinogen, factor XII, fibrillin and fibrillin-rich microfibrils, as well as the serpins PAI-2 and α2-antichymotrypsin. 13 We previously showed that normal bronchial epithelial repair following mechanical wounding is dependent on coagulation factor expression and fibrin formation. 10 In our model of normal bronchial epithelial repair following viral infection, 
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F I G U R E 4 DMF enhances bronchial epithelial repair. A, DMF alone (black bars) had no effect on the rate of epithelial repair in 16HBE cells, but in the presence of 20 μg/mL poly I:C (grey bars), DMF at 10 and 50 μmol/L significantly enhances the rate of repair compared to the effect of poly I:C alone. *P < 0.05, **P < 0.01 compared with DMF alone. P < 0.05 compared to poly I:C alone (n = 3). B, Poly I:C (1-20 μg/mL) alone (black bars) inhibits the rate of NHBE repair and addition of 50 μmol/L DMF (grey bars) significantly reversed the effect of poly I:C at all concentrations tested. **P < 0.01 compared to the no poly I:C control. P < 0.05, P < 0.01 compared to the poly I:C alone control (n = 3 or 4) 
F I G U R E 5 The effect of poly I:C on TF release by bronchial epithelial cell layers. Poly I:C strongly stimulated TF release from intact and wounded 16HBE bronchial epithelial cell layers, **P < 0.01, ***P < 0.001 compared with the no poly I:C control (n = 4). Poly I:C had no effect on TF release from wounded NHBE cell layers (n = 4) increased MMP-13 activity is proposed to degrade coagulation factors and matrix proteins essential for successful epithelial repair. The MMP-13 inhibitor WAY 170523 significantly enhanced the rate of repair of NHBE cell layers, suggesting a potent inhibitory effect of MMP-13 activity on normal bronchial epithelial repair.
Secretion of MMP-13 was previously shown to be strongly induced by poly I:C acting on small airway epithelial cells, 15 an effect mediated via release of IFN-β and interferon receptor pathways. 21 Increased expression of MMP-13 was also reported in primary tracheobronchial airway epithelial cells infected with both respiratory syncytial virus and influenza A. 22 Together with our findings in Inhibitors of MMP-13 activity, including selective inhibitors 27, 28 and specific neutralising antibodies 29 that avoid the side-effects of broad-spectrum MMP inhibitors, are currently in development for the treatment of arthritis, cancer and cardiac disease, with the potential for repurposing for respiratory disease. Other approaches include inhibition of MMP-13 expression. DMF was previously shown to attenuate MMP-13 expression in isolated chondrocytes by inhibiting the JAK/STAT3 pathway. 18 Our results provide evidence that DMF similarly attenuates MMP-13 expression in bronchial epithelial cells and has a positive effect on epithelial repair. DMF was originally developed to treat inflammatory skin disease such as psoriasis and was recently repurposed to treat multiple sclerosis. 30 Others recently proposed repurposing DMF as an anti-inflammatory therapy for asthma, 31 and we now suggest that DMF may also limit inflammation indirectly through positive effects on bronchial epithelial repair.
Of particular further interest are the recent reports that the leukotriene receptor antagonist montelukast not only suppresses inflammation in a poly I:C-induced asthma exacerbation model in mice, 32 but also suppresses LPS-induced MMP-13 expression in mouse osteoblasts. 33 However, the effects of montelukast on bronchial epithelial repair in our model remain to be investigated.
Bosentan was previously shown to inhibit MMP-13 release from primary bronchial epithelial cells stimulated with TNF-α. 19 However, although we demonstrated that poly I:C (20 μg/mL) induced endothelin release from NHBE ( Figure 6A ), the positive effect of bosentan on the rate of epithelial repair in the presence of poly I:C (20 μg/mL) was not related to inhibition of MMP-13 release. Alternatively, endothelin-1 was previously shown to result in slower migration of primary bronchial epithelial cells across uncoated filters. 34 In our experiments, the strong positive effect of bosentan on epithelial repair in the presence of poly I:C may reflect inhibition of endogenously produced endothelin-1 acting in an autocrine fashion on endothelin receptors A and/or B expressed on primary bronchial epithelial cells 35 to limit the rate of cell migration. Figure 7 illustrates our proposed mechanisms for defective bronchial epithelial repair following virus infection, identifying targets and drugs to improve repair.
Endothelin-1 is a potent bronchoconstrictor and proinflammatory mediator that plays a role in the pathogenesis of lung diseases, including asthma, and in the comorbidities associated with COPD.
36
A role for endothelin receptor antagonists and the repurposing of bosentan, approved for pulmonary arterial hypertension, for asthma was proposed. 37 Although treatment with oral bosentan for 4 weeks did not improve lung function or symptom score in difficult to control asthma, 38 it was suggested that local delivery via inhalation may enhance the potency and efficacy of repurposed drugs for allergy and asthma, while avoiding the systemic adverse side-effects. 37 Animal models have indicated the feasibility of this approach for bosentan. 39, 40 The limitations of the study that influence the final conclusions are that analysis was performed only in normal NHBE, and the results have yet to be confirmed in diseased cells. Additionally, the results
were not confirmed in differentiated epithelial cells, using the air- liquid interface (ALI) model. However, others 41 have shown that NHBE in ALI close by only 20% even at 48 hours, which was suggested to be due to technical issues with using ALI for wound repair assays.
Overall, the mechanisms by which respiratory viruses limit the repair response are not well understood and this is an important research area for identifying therapeutic targets aimed at enhancing epithelial repair. Chronic airways diseases such as asthma and COPD are associated with repeated cycles of injury and repair. Derangements in bronchial epithelial function may contribute to epithelial fragility and airway remodelling, 42 and the epithelium is therefore a particular target for focused therapeutic interventions in asthma 43, 44 and COPD. 2 Overall, our results lead us to propose a novel MMP-13-dependent mechanism for defective bronchial epithelial repair following virus infection. However, further studies using primary cells from patients are needed to confirm whether MMP-13 inhibitors and endothelin receptor antagonists repurposed for inhalation may be useful therapeutic approaches in asthma and COPD.
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